Boehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDA

Biotech group Zealand Pharma and German partner Boehringer Ingelheim have been given fast track designation by the US FDA for drug candidate BI 456906 meant to treat nonalcoholic steatohepatitis (Nash), Zealand Pharma reveals Wednesday.

Photo: Zealand Pharma / PR

Danish biotechnology firm Zealand Pharma and its German partner, Boehringer Ingelheim, can look forward to expedited case processing time of their drug candidate BI 456906 from the US Food and Drug Administration (FDA) now that the treatment has received fast-track status, informs Zealand Pharma in a statement Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs